Incidental Detection of Medullary Thyroid Carcinoma by 68Ga-DOTATATE PET/CT in a Patient With Neuroendocrine Tumor Liver Metastases. uri icon

Overview

abstract

  • Ga-DOTATATE, a positron-emitting somatostatin analog, has been approved by the Food and Drug Administration for imaging neuroendocrine tumors (NETs). The presence of a second primary malignancy is common in NETs; however, synchronous primary malignancy in the thyroid has rarely been reported. The value of Ga-DOTATATE in medullary thyroid cancer is being investigated and is currently recommended for use when treatment with somatostatin analogs is an option. We present a 55-year-old man with abdominal pain associated with well-differentiated NET liver metastases and incidental medullary thyroid carcinoma demonstrated on a Ga-DOTATATE PET/CT.

publication date

  • February 1, 2018

Research

keywords

  • Carcinoma, Neuroendocrine
  • Incidental Findings
  • Liver Neoplasms
  • Neuroendocrine Tumors
  • Organometallic Compounds
  • Positron Emission Tomography Computed Tomography
  • Thyroid Neoplasms

Identity

PubMed Central ID

  • PMC5666645

Scopus Document Identifier

  • 85040776598

Digital Object Identifier (DOI)

  • 10.1097/RLU.0000000000001950

PubMed ID

  • 29261627

Additional Document Info

volume

  • 43

issue

  • 2